The VeriSeq^™ NIPT Solution provides accurate information about fetal chromosome status as early as 10 weeks gestation using a single maternal blood draw. This noninvasive screen yields results for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), as well as certain sex chromosome-related disorders. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures. "As a proud partner of Illumina, we are thrilled to soon use the new VeriSeq^™ NIPT protocol to power our NIPT test, Serenity,” said Tony Gordon, PhD, Vice President of Business Development for Cooper Genomics. "The advances offered by VeriSeq^™ NIPT will allow us to provide results to our clinical partners faster, with high sensitivity and minimal test failures.” Read more